Cingulate Therapeutics currently has two (2) products in pre-clinical development for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
CTX-1301 and CTX-1302 are both highly innovative products designed to fulfill long-standing unmet needs of patients suffering with ADHD. The company’s lead product, CTX-1301, is expected to complete initial Phase I/Phase II human trials in early 2016.
ADHD is a neurobiological disorder diagnosed via well-understood and validated clinical assessments.
In the United States, it is estimated that 7-8% of children and adolescents have ADHD (approximately 5 million patients). It is estimated that 50-65% of these individuals demonstrate clinical ADHD symptoms that persist into adulthood. The resulting adult ADHD prevalence is estimated at 4.4% of the population (10 million patients), double that of the child and adolescent segment.
An estimated 60% of children and adolescents diagnosed with ADHD receive pharmacologic treatment while only 20% of adults are currently treated.